FIXX - Homology Medicines Inc Stock Price, Fair Value and News

30.47USD+0.11 (+0.36%)Delayed

Market Summary

USD30.47+0.11

Delayed

0.36%

FIXX Stock Price

View Fullscreen

FIXX RSI Chart

FIXX Valuation

Market Cap

363.9M

Price/Earnings (Trailing)

-15.23

Price/Sales (Trailing)

112.1

EV/EBITDA

-4.68

Price/Free Cashflow

-52.35

FIXX Price/Sales (Trailing)

FIXX Profitability

EBT Margin

-1645.87%

Return on Equity

-49%

Return on Assets

-15.69%

Free Cashflow Yield

-1.91%

FIXX Fundamentals

FIXX Revenue

Revenue (TTM)

3.2M

Rev. Growth (Yr)

-100%

Rev. Growth (Qtr)

-100%

FIXX Earnings

Earnings (TTM)

-23.9M

Earnings Growth (Yr)

103.47%

Earnings Growth (Qtr)

-97.68%

Breaking Down FIXX Revenue

Last 7 days

15.5%

Last 30 days

25.7%

Last 90 days

111.6%

Trailing 12 Months

62.8%

How does FIXX drawdown profile look like?

FIXX Financial Health

Current Ratio

4.19

FIXX Investor Care

Shares Dilution (1Y)

271.93%

Diluted EPS (TTM)

-4.74

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	0	0	0	0
2023	7.3M	6.9M	7.5M	3.2M
2022	27.1M	20.3M	13.5M	6.7M
2021	31.4M	33.0M	34.1M	34.0M
2020	1.9M	2.2M	2.4M	2.7M
2019	4.5M	4.8M	4.9M	1.7M
2018	0	0	4.3M	4.3M
2017	0	0	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Homology Medicines Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 25, 2024	alloway paul	acquired	-	-	23,530	see remarks
Mar 25, 2024	michaud charles jr	acquired	-	-	6,448	see remarks
Jan 09, 2024	tzianabos arthur	sold	-7,445	0.5711	-13,037	-
Jan 03, 2024	alloway paul	sold	-4,120	0.566	-7,280	see remarks
Jan 03, 2024	michaud charles jr	sold	-975	0.571	-1,708	see remarks
Jan 01, 2024	michaud charles jr	acquired	-	-	4,240	see remarks
Jan 01, 2024	tzianabos arthur	acquired	-	-	33,420	-
Jan 01, 2024	alloway paul	acquired	-	-	18,610	see remarks
Sep 06, 2023	seymour albert	acquired	-	-	4,620	see remarks
Sep 06, 2023	seymour albert	sold	-1,665	1.1502	-1,448	see remarks

Which funds bought or sold FIXX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	JANE STREET GROUP, LLC	sold off	-100	-14,379	-	-%
May 15, 2024	Newtyn Management, LLC	sold off	-100	-850,750	-	-%
May 15, 2024	STATE STREET CORP	sold off	-100	-81,353	-	-%
May 15, 2024	Tudor Investment Corp Et Al	sold off	-100	-70,299	-	-%
May 15, 2024	HSBC HOLDINGS PLC	sold off	-100	-9,320	-	-%
May 15, 2024	MORGAN STANLEY	sold off	-100	-7,939	-	-%
May 15, 2024	BANK OF AMERICA CORP /DE/	sold off	-100	-114,894	-	-%
May 15, 2024	BARCLAYS PLC	sold off	-100	-33,000	-	-%
May 15, 2024	ADAR1 Capital Management, LLC	sold off	-100	-178,555	-	-%
May 15, 2024	5AM Venture Management, LLC	sold off	-100	-2,757,840	-	-%

Are Funds Buying or Selling FIXX?

Are funds buying FIXX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own FIXX

No. of Funds

Unveiling Homology Medicines Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
May 13, 2024	arch venture fund viii, l.p.	-	0	SC 13G/A
Apr 04, 2024	acorn bioventures, l.p.	6.7%	803,425	SC 13D
Apr 01, 2024	atlas venture fund x, l.p.	7.2%	864,261	SC 13D
Mar 29, 2024	carlyle group inc.	9.2%	1,102,741	SC 13G
Mar 28, 2024	orbimed advisors llc	18.9%	2,252,987	SC 13D
Jul 08, 2022	blackrock inc.	2.9%	1,656,676	SC 13G
Feb 14, 2022	temasek holdings (private) ltd	9.9%	5,650,996	SC 13G/A
Feb 03, 2022	blackrock inc.	6.3%	3,587,777	SC 13G/A
May 06, 2021	jpmorgan chase & co	2.0%	1,185,457	SC 13G/A
Feb 16, 2021	price t rowe associates inc /md/	4.3%	1,986,298	SC 13G/A

Recent SEC filings of Homology Medicines Inc

View All Filings

Date Filed	Form Type	Document
May 13, 2024	SC 13G/A	Major Ownership Report
May 09, 2024	10-Q	Quarterly Report
May 09, 2024	424B3	Prospectus Filed
May 09, 2024	8-K	Current Report
Apr 29, 2024	EFFECT	EFFECT
Apr 29, 2024	424B3	Prospectus Filed
Apr 23, 2024	4	Insider Trading
Apr 23, 2024	4	Insider Trading
Apr 19, 2024	S-1	Initial Public Offering
Apr 12, 2024	10-K/A	Annual Report

Peers (Alternatives to Homology Medicines Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	233.93%	75.07%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Homology Medicines Inc News

Latest updates

Homology Medicines Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	-	-	-	1,423,000	354,000	1,469,000	4,245,000	802,000	802,000	802,000	802,000	1,677,000	2,187,000	29,305,000	980,000	567,000	567,000	588,000	1,124,500	1,661,000	1,703,000	1,271,000
Operating Expenses	130.4%	14,843,000	-48,880,000	31,001,000	31,170,000	28,313,000	-55,317,000	33,664,000	29,109,000	38,420,000	34,427,000	32,338,000	32,739,000	30,416,000	30,781,500	28,840,000	36,264,000	37,080,000	26,122,000	31,729,000	28,365,000	25,393,000
S&GA Expenses	100.0%	-	-13,480,000	6,842,000	8,188,000	8,325,000	-19,929,000	7,810,000	8,034,000	14,147,000	10,781,000	8,351,000	9,042,000	8,661,000	7,587,000	8,423,000	8,793,000	7,770,000	5,779,000	6,038,000	5,538,000	4,857,000
R&D Expenses	134.2%	9,841,000	-28,760,000	17,519,000	22,982,000	19,988,000	-35,388,000	25,854,000	21,075,000	24,273,000	23,646,000	23,987,000	23,697,000	21,755,000	23,194,500	20,417,000	27,471,000	29,310,000	20,343,000	25,691,000	22,827,000	20,536,000
EBITDA Margin	0%	-16.32	-16.32	-21.62	-23.84	-22.17	-6.38	0.27	0.32	0.20	-2.57	-	-	-	-	-	-	-	-	-	-	-
Income Taxes	-100.0%	-	318,000	-	-	-	-851,000	-46,000	105,000	967,000	-	-	-	-	-	-	-	-	-	-	-	-
Earnings Before Taxes	-100.0%	-	31,500,000	-29,578,000	-29,305,000	-26,042,000	-76,984,000	-31,593,000	-27,833,000	93,663,000	-33,583,000	-30,608,000	-30,500,000	-1,073,000	-	-	-	-	-	-	-	-
EBT Margin	0%	-16.46	-16.46	-21.61	-23.86	-22.20	-6.43	0.05	0.08	-0.04	-2.82	-	-	-	-	-	-	-	-	-	-	-
Net Income	-97.7%	1,000,000	43,099,000	-32,954,000	-35,044,000	-28,844,000	-72,099,000	-33,726,000	-29,089,000	92,105,000	-33,583,000	-30,608,000	-30,500,000	-1,073,000	-29,791,000	-28,232,000	-35,340,000	-35,331,000	-24,167,000	-29,627,000	-26,270,000	-23,852,000
Net Income Margin	55.5%	-7.36	-16.56	-22.55	-24.70	-22.38	-6.44	-0.32	-0.06	-0.10	-2.82	-2.69	-2.71	-	-	-	-	-	-	-	-	-
Free Cashflow	-125.9%	-14,551,000	56,201,000	-24,941,000	-23,660,000	-26,282,000	74,296,000	-24,938,000	-30,967,000	-31,833,000	-30,768,000	-25,864,000	-24,875,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	223.7%	152	47.00	140	169	198	62.00	263	285	311	212	231	259	235	264	228	258	289	311	317	341	233
Current Assets	380.7%	138	29.00	107	131	154	47.00	213	238	262	192	192	218	192	220	181	210	238	267	274	299	191
Cash Equivalents	353.4%	116	26.00	29.00	77.00	39.00	44.00	43.00	176	248	33.00	96.00	116	104	217	178	168	143	54.00	78.00	116	41.00
Net PPE	-6.9%	2.00	2.00	-	1.00	1.00	2.00	1.00	2.00	2.00	2.00	33.00	34.00	36.00	37.00	40.00	41.00	43.00	43.00	41.00	41.00	41.00
Liabilities	-12.6%	104	119	52.00	50.00	46.00	81.00	54.00	44.00	45.00	42.00	32.00	34.00	34.00	68.00	58.00	64.00	62.00	52.00	59.00	56.00	59.00
Current Liabilities	133.6%	33.00	14.00	25.00	23.00	19.00	58.00	25.00	21.00	21.00	17.00	19.00	20.00	18.00	23.00	17.00	20.00	17.00	12.00	19.00	15.00	18.00
Long Term Debt	-100.0%	-	39.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
LT Debt, Current	-	-	-	-	-	-	32.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
LT Debt, Non Current	-100.0%	-	39.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Shareholder's Equity	-33.2%	49.00	73.00	88.00	119	152	178	209	240	266	170	199	225	201	196	170	195	227	259	258	285	174
Retained Earnings	0.5%	-186	-187	-525	-493	-457	-133	-394	-361	-332	-424	-390	-359	-329	-328	-298	-270	-235	-199	-175	-145	-119
Additional Paid-In Capital	5546.2%	235	4.00	614	612	610	3.00	604	601	598	594	589	585	530	524	469	465	462	458	433	430	294
Shares Outstanding	59.6%	12.00	7.00	3.00	3.00	3.00	7.00	3.00	3.00	3.00	3.00	3.00	3.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	46.00	-	-	-	92.00	-	-	-	339	-	-	-	512	-	-	-	514	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-126.0%	-14,551	55,978	-24,941	-23,660	-26,054	75,505	-24,932	-30,846	-30,684	-30,430	-25,387	-24,111	-29,823	-11,612	-28,887	-27,987	-25,846	-26,333	-25,484	-21,670	-17,871
Share Based Compensation	108.3%	417	-5,049	1,706	2,402	2,369	-8,727	2,771	3,143	4,051	4,663	4,226	4,473	3,883	3,566	3,346	3,453	2,883	2,436	1,986	1,970	1,243
Cashflow From Investing	100.1%	97.00	-69,615	-22,763	61,001	31,372	-21,191	-108,218	-41,369	168,312	43,661	4,524	-13,738	-85,235	-955	38,844	52,010	114,997	-20,027	-13,137	-38,302	19,667
Cashflow From Financing	41995.8%	99,346	236	18.00	2.00	150	29,505	124	-	440	1.00	379	49,746	2,043	51,995	410	241	447	22,575	614	134,699	325

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

FIXX Income Statement

2024-03-31

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
Collaboration arrangement revenue	$ 0	$ 2,947
Operating expenses:
Research and development	9,841	7,910
General and administrative	5,002	2,410
Total operating expenses	14,843	10,320
Loss from operations	(14,843)	(7,373)
Change in fair value of convertible notes	15,890	(43)
Other income (expense), net	158	578
Total other income (expense), net	16,048	535
Income (loss) before provision for income taxes	1,205	(6,838)
Loss from equity method investment	(176)	0
Net income (loss)	$ 1,029	$ (6,838)
Net income (loss) per share - basic	$ 1.03	$ (19.84)
Net income (loss) per share - diluted	$ (6.33)	$ (19.84)
Weighted-average common shares - basic	995,280	344,623
Weighted-average common shares - diluted	2,334,180	344,623

FIXX Balance Sheet

2024-03-31

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 115,509	$ 25,617
Short-term investments	19,803	0
Prepaid expenses and other current assets	2,731	3,099
Total current assets	138,043	28,716
Equity method investment	4,724	0
Property and equipment, net	1,659	1,782
Right-of-use asset, operating leases	6,160	6,301
Restricted cash and restricted cash equivalents	647	5,647
Other noncurrent assets	1,101	4,611
Total assets	152,334	47,057
Current liabilities:
Accounts payable	4,960	3,468
Accrued expenses and other current liabilities	19,825	9,763
CVR liability	5,080	0
Venture debt, current portion	3,088	878
Total current liabilities	32,953	14,109
Lease liability, net of current portion	6,099	6,248
Venture debt, net of current portion	9,400	4,581
Convertible notes	0	38,595
Other noncurrent liabilities	55,113	55,000
Total liabilities	103,565	118,533
Commitments and contingencies (Note 10)
Temporary equity, convertible preferred stock	0	111,445
Stockholders' deficit:
Common stock, $0.0001 par value; 400,000,000 shares authorized, 11,929,520 and 359,569 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively	2	1
Additional paid-in capital	234,824	4,159
Accumulated other comprehensive loss	(5)	0
Accumulated deficit	(186,052)	(187,081)
Total stockholders' equity (deficit)	48,769	(182,921)
Total liabilities, convertible preferred stock and stockholders' deficit	152,334	47,057
Series A convertible preferred stock [Member]
Current liabilities:
Temporary equity, convertible preferred stock	0	47,458
Series A-1 convertible preferred stock [Member]
Current liabilities:
Temporary equity, convertible preferred stock	0	4,132
Series B convertible preferred stock [Member]
Current liabilities:
Temporary equity, convertible preferred stock	$ 0	$ 59,855

About Homology Medicines Inc

Homology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a nuclease-free gene editing mobility, gene therapy or for various genetic disorders. The company's various set of AAVHSCs allows company to precisely target, through a single injection, a range of disease-relevant tissues, including the liver, central nervous system, peripheral nervous system, blood-brain-barrier, bone marrow, cardiac and skeletal muscle, and eye. Its lead product candidate is HMI-102, which is in Phase 2 pheNIX clinical trial, a gene therapy for the treatment of phenylketonuria (PKU) in adults. The company also develops HMI-103 for the treatment of PKU in pediatric patients; HMI-202 to treat metachromatic leukodystrophy; and HMI-203 for the treatment of mucopolysaccharidosis type II, as well as HMI-104 for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Homology Medicines, Inc. was incorporated in 2015 and is headquartered in Bedford, Massachusetts.

CEO	Dr. Albert Seymour Ph.D.
WEBSITE	homologymedicines.com
INDUSTRY	Biotechnology
EMPLOYEES	92

Homology Medicines Inc Frequently Asked Questions

What is the ticker symbol for Homology Medicines Inc? What does FIXX stand for in stocks?

FIXX is the stock ticker symbol of Homology Medicines Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Homology Medicines Inc (FIXX)?

As of Fri May 17 2024, market cap of Homology Medicines Inc is 363.88 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of FIXX stock?

You can check FIXX's fair value in chart for subscribers.

What is the fair value of FIXX stock?

You can check FIXX's fair value in chart for subscribers. The fair value of Homology Medicines Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Homology Medicines Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for FIXX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Homology Medicines Inc a good stock to buy?

The fair value guage provides a quick view whether FIXX is over valued or under valued. Whether Homology Medicines Inc is cheap or expensive depends on the assumptions which impact Homology Medicines Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for FIXX.

What is Homology Medicines Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, FIXX's PE ratio (Price to Earnings) is -15.23 and Price to Sales (PS) ratio is 112.1. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. FIXX PE ratio will change depending on the future growth rate expectations of investors.